Cancer Prevention Institute of California, 2201 Walnut Avenue, Suite 300, Fremont, CA 94538, USA.
Cancer Causes Control. 2010 Dec;21(12):2241-8. doi: 10.1007/s10552-010-9647-x. Epub 2010 Oct 6.
To investigate whether obesity and hormone therapy (HT) are associated with ovarian cancer risk among women in the California Teachers Study cohort.
Of 56,091 women age ≥ 45 years, 277 developed epithelial ovarian cancer between 1995 and 2007. Multivariate Cox regression was performed.
Among women who never used HT, greater adult weight gain, waist circumference and waist-to-height ratio, but not adult BMI, increased risk of ovarian cancer. Compared to women who never used HT and had a stable adult weight, risk of ovarian cancer was increased in women who gained ≥ 40 lb (relative risk (RR) 1.8, 95% confidence interval (CI): 1.0-3.0) or used HT for >5 years (RR 2.3 95% CI: 1.3-4.1). Having both exposures (RR 1.9, 95% CI: 0.99-3.5), however, did not increase risk more than having either alone. Results were similar for waist circumference and weight-to-height ratio; however, differences across HT groups were not statistically significant.
This study suggests that abdominal adiposity and weight gain, but not overall obesity, increase ovarian cancer risk and that there may be a threshold level beyond which additional hormones, whether exogenous or endogenous, do not result in additional elevation in risk. However, large pooled analyses are needed to confirm these findings.
在加利福尼亚教师研究队列中,研究肥胖和激素疗法(HT)是否与女性卵巢癌风险相关。
在 56091 名年龄≥45 岁的女性中,有 277 名在 1995 年至 2007 年间发生上皮性卵巢癌。采用多变量 Cox 回归进行分析。
在从未使用 HT 的女性中,体重增加、腰围和腰高比的增加,而不是成人 BMI,与卵巢癌风险增加有关。与从未使用 HT 且体重稳定的女性相比,体重增加≥40 磅(相对风险(RR)1.8,95%置信区间(CI):1.0-3.0)或使用 HT 超过 5 年(RR 2.3,95% CI:1.3-4.1)的女性,卵巢癌风险增加。然而,同时存在这两种暴露因素(RR 1.9,95% CI:0.99-3.5),并不比单独存在任何一种因素的风险更高。腰围和体重与身高比的结果相似;然而,HT 组之间的差异没有统计学意义。
本研究表明,腹部肥胖和体重增加,但不是整体肥胖,会增加卵巢癌的风险,并且可能存在一个阈值水平,超过该水平后,无论是外源性还是内源性的额外激素都不会导致风险进一步升高。然而,需要进行大型的汇总分析来证实这些发现。